These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 38333738)
1. Corrigendum: Wastewater-based surveillance identifies start to the pediatric respiratory syncytial virus season in two cities in Ontario, Canada. Mercier E; Pisharody L; Guy F; Wan S; Hegazy N; D'Aoust PM; Kabir MP; Nguyen TB; Eid W; Harvey B; Rodenburg E; Rutherford C; Mackenzie AE; Willmore J; Hui C; Paes B; Delatolla R; Thampi N Front Public Health; 2024; 12():1354693. PubMed ID: 38333738 [TBL] [Abstract][Full Text] [Related]
2. Wastewater-based surveillance identifies start to the pediatric respiratory syncytial virus season in two cities in Ontario, Canada. Mercier E; Pisharody L; Guy F; Wan S; Hegazy N; D'Aoust PM; Kabir MP; Nguyen TB; Eid W; Harvey B; Rodenburg E; Rutherford C; Mackenzie AE; Willmore J; Hui C; Paes B; Delatolla R; Thampi N Front Public Health; 2023; 11():1261165. PubMed ID: 37829087 [TBL] [Abstract][Full Text] [Related]
3. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173 [TBL] [Abstract][Full Text] [Related]
4. Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes. Oh PI; Lanctôt KL; Yoon A; Lee DS; Paes BA; Simmons BS; Parison D; Manzi P; Pediatr Infect Dis J; 2002 Jun; 21(6):512-8. PubMed ID: 12182374 [TBL] [Abstract][Full Text] [Related]
5. Updated cost-effectiveness analysis of palivizumab (Synagis) for the prophylaxis of respiratory syncytial virus in infant populations in the UK. Narayan O; Bentley A; Mowbray K; Hermansson M; Pivonka D; Kemadjou EN; Belsey J J Med Econ; 2020 Dec; 23(12):1640-1652. PubMed ID: 33107769 [TBL] [Abstract][Full Text] [Related]
6. Respiratory Syncytial Virus Prophylaxis in Infants With Congenital Diaphragmatic Hernia in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab, 2005-2017. Kim D; Saleem M; Paes B; Mitchell I; Lanctôt KL Clin Infect Dis; 2019 Aug; 69(6):980-986. PubMed ID: 30517603 [TBL] [Abstract][Full Text] [Related]
7. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage. Romero JR Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452 [TBL] [Abstract][Full Text] [Related]
9. Seasonal respiratory syncytial virus prophylaxis based on predetermined dates versus regional surveillance data. Paes BA; Craig C; Pigott W; Latchman A Pediatr Infect Dis J; 2013 Sep; 32(9):e360-4. PubMed ID: 23546534 [TBL] [Abstract][Full Text] [Related]
10. Optimizing the delivery and use of a new monoclonal antibody in children with congenital heart disease: a successful provincial respiratory syncytial virus prophylaxis program. Warren A; Langley JM; Thomas W; Scott J Can J Cardiol; 2007 May; 23(6):463-6. PubMed ID: 17487291 [TBL] [Abstract][Full Text] [Related]
11. Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants. Pediatrics; 1998 Sep; 102(3):531-7. PubMed ID: 9724660 [TBL] [Abstract][Full Text] [Related]
12. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses. Wang D; Bayliss S; Meads C Health Technol Assess; 2011 Jan; 15(5):iii-iv, 1-124. PubMed ID: 21281564 [TBL] [Abstract][Full Text] [Related]
13. Wastewater Surveillance Data as a Complement to Emergency Department Visit Data for Tracking Incidence of Influenza A and Respiratory Syncytial Virus - Wisconsin, August 2022-March 2023. DeJonge PM; Adams C; Pray I; Schussman MK; Fahney RB; Shafer M; Antkiewicz DS; Roguet A MMWR Morb Mortal Wkly Rep; 2023 Sep; 72(37):1005-1009. PubMed ID: 37708080 [TBL] [Abstract][Full Text] [Related]
14. Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada. Paes B; Steele S; Janes M; Pinelli J Curr Med Res Opin; 2009 Jul; 25(7):1585-91. PubMed ID: 19469698 [TBL] [Abstract][Full Text] [Related]
15. RSV Hospitalizations in Comparison With Regional RSV Activity and Inpatient Palivizumab Administration, 2010-2013. Glick AF; Kjelleren S; Hofstetter AM; Subramony A Hosp Pediatr; 2017 May; 7(5):271-278. PubMed ID: 28381595 [TBL] [Abstract][Full Text] [Related]
16. Study protocol: a multicenter, uncontrolled, open-label study of palivizumab in neonates, infants, and preschool children at high risk of severe respiratory syncytial virus infection. Mori M; Watabe S; Taguchi T; Hasegawa H; Ishige M; Tanuma N; Hirakawa A; Koike R; Kusuda S BMC Pediatr; 2021 Mar; 21(1):106. PubMed ID: 33653291 [TBL] [Abstract][Full Text] [Related]
17. Respiratory illness and respiratory syncytial virus hospitalization in infants with a tracheostomy following prophylaxis with palivizumab. Paes B; Saleem M; Kim D; Lanctôt KL; Mitchell I Eur J Clin Microbiol Infect Dis; 2019 Aug; 38(8):1561-1568. PubMed ID: 31119575 [TBL] [Abstract][Full Text] [Related]
18. Impact of the 2014 American Academy of Pediatrics recommendation and of the resulting limited financial coverage by the Italian Medicines Agency for palivizumab prophylaxis on the RSV-associated hospitalizations in preterm infants during the 2016-2017 epidemic season: a systematic review of seven Italian reports. Cutrera R; Wolfler A; Picone S; Rossi GA; Gualberti G; Merolla R; Del Vecchio A; Villani A; Midulla F; Dotta A Ital J Pediatr; 2019 Nov; 45(1):139. PubMed ID: 31706338 [TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Joffe S; Ray GT; Escobar GJ; Black SB; Lieu TA Pediatrics; 1999 Sep; 104(3 Pt 1):419-27. PubMed ID: 10469764 [TBL] [Abstract][Full Text] [Related]
20. Access to palivizumab among children at high risk of respiratory syncytial virus complications in English hospitals. Zylbersztejn A; Almossawi O; Gudka N; Tompsett D; De Stavola B; Standing JF; Smyth R; Hardelid P Br J Clin Pharmacol; 2022 Mar; 88(3):1246-1257. PubMed ID: 34478568 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]